Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer
Leap Therapeutics and BeiGene have started dosing patients in a trial combining an anti-PD-1 antibody with the novel targeted drug DKN-01 in... Read More
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
In a recent trial, Keytruda was found to be as effective as chemotherapy in previously untreated gastric cancer patients, but it caused... Read More
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma
Combining Cyramza with IMFINZI® (durvalumab) was safe and effective in a small trial that included gastric cancer patients.
Pieris and Lilly enter into a Clinical Trial Collaboration to Evaluate Combination of PRS-343 with Ramucirumab and Paclitaxel in Gastric Cancer
Pieris and Eli Lilly have partnered to test a combination of Cyramza, paclitaxel and Pieris’ novel bispecific antibody in HER2-positive gastric cancer.
First US clinical trial testing efficacy of delivering aerosolized chemotherapy
City of Hope is recruiting patients with gastric cancer for a trial of a chemotherapy spray that can be delivered straight to... Read More
Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
RemeGen announced a 24% response rate in a clinical trial of its antibody drug conjugate RC48 in patients with HER-2 positive gastric... Read More
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer
A recent trial of a combination of Stivarga and Opdivo showed better activity than either drug alone in patients with gastric cancer.
Preventing Gastric Cancer Development by Inhibiting the Virulence of H. pylori Infection
New clinical trials will examine the use of the drug DFMO for preventing gastric cancer in people with the H. Pylori infection